Absolute survival after cardiac resynchronization therapy according to baseline QRS duration: A multinational 10-year experience: Data from the Multicenter International CRT Study

Maurizio Gasparini, Christophe Leclercq, Cheuk Man Yu, Angelo Auricchio, Jonathan S. Steinberg, Barbara Lamp, Catherine Klersy, Francisco Leyva

Research output: Contribution to journalArticlepeer-review

Abstract

Background In the major trials of cardiac resynchronization therapy (CRT), the survival benefit of the therapy, relative to control subjects, increases with QRS duration. In the non-CRT heart failure population, however, a wide QRS duration is associated with a shorter survival. Relative survival benefit from a therapy, however, is not synonymous with a longer absolute survival. We sought to determine whether baseline QRS duration relates to the absolute survival after CRT. Methods and Results In this prospective, longitudinal, observational study, 3,319 consecutive patients undergoing CRT (QRS 120-149 ms 26%, QRS 150-199 ms 58%, and QRS ≥200 ms 16%) were assessed in relation to mortality over 10 years. Overall mortality rates (per 100 patient-years) were 9.2%, 9.3%, and 13.3% in the 3 groups, respectively (all P

Original languageEnglish
JournalAmerican Heart Journal
Volume167
Issue number2
DOIs
Publication statusPublished - Feb 2014

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Absolute survival after cardiac resynchronization therapy according to baseline QRS duration: A multinational 10-year experience: Data from the Multicenter International CRT Study'. Together they form a unique fingerprint.

Cite this